Eurofins Discovery’s mission is to support Pharmaceutical and Biotech companies in their efforts to accelerate drug discovery research and development.  The COVID-19 crisis is putting the focus on the need for drugs and vaccines to treat patients and provide protection to the global population. Through its worldwide presence, depth of scientific experience, and breadth of assays and services, Eurofins Discovery is striving to provide expert support in identifying and assessing potential drug targets.

Pharmaceutical, biotech, government, and non-profit organizations are working diligently to identify new or existing drug modalities that potentially can be used to treat COVID-19 affected populations.  Some of these antiviral treatment strategies include targeting angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and SARS-CoV-2 M^pro, as well as large molecule therapies. Eurofins Discovery provides the experience, reliability, global locations, and breadth of custom and off-the-shelf services and products to support researchers in these endeavors.

The Eurofins Discovery solution portfolio that can support COVID-19 research include:

• Safety profiling
• Efficacy testing
• Custom assay development
• Drug repositioning services
• Bioassays and target specific assays
• Cytokine storm assessment.  As recommended by the FDA and EMA, early-stage evaluation of cellular activation, proliferation, and cytokine release, as offered by Eurofins Discovery, may help reduce the risk of adverse reactions in later clinical development.

Eurofins Discovery provides a vast product and service portfolio for drug discovery and a global team of experts that are ready to work on this global problem. For more information on Eurofins Discovery’s comprehensive services and products supporting COVID-19 research

Source: https://www.prnewswire.com/news-releases/eurofins-discovery-supports-critical-covid-19-drug-discovery-research-with-products-and-accelerated-drug-discovery-services-301038986.html